These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20602727)

  • 1. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder.
    Okuda A; Suzuki T; Kishi T; Yamanouchi Y; Umeda K; Haitoh H; Hashimoto S; Ozaki N; Iwata N
    Psychiatry Clin Neurosci; 2010 Jun; 64(3):268-73. PubMed ID: 20602727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of untreated illness in major depressive disorder: a naturalistic study.
    Altamura AC; Dell'Osso B; Mundo E; Dell'Osso L
    Int J Clin Pract; 2007 Oct; 61(10):1697-700. PubMed ID: 17877655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population.
    Kishi T; Kitajima T; Ikeda M; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Ozaki N; Iwata N
    Neuropsychobiology; 2009; 59(4):234-8. PubMed ID: 19571598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population.
    Okumura T; Kishi T; Okochi T; Ikeda M; Kitajima T; Yamanouchi Y; Kinoshita Y; Kawashima K; Tsunoka T; Inada T; Ozaki N; Iwata N
    Neuropsychobiology; 2010; 61(2):57-63. PubMed ID: 20016223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder.
    Dell'Osso B; Buoli M; Hollander E; Altamura AC
    World J Biol Psychiatry; 2010 Feb; 11(1):59-65. PubMed ID: 20001657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression.
    Zanardi R; Cusin C; Rossini D; De Ronchi D; Serretti A
    J Clin Psychopharmacol; 2003 Dec; 23(6):535-9. PubMed ID: 14624182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study.
    Ciudad A; Álvarez E; Roca M; Baca E; Caballero L; García de Polavieja P; Casillas M; Valladares A; Gilaberte I
    J Clin Psychiatry; 2012 Feb; 73(2):185-91. PubMed ID: 22053897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables.
    Dotoli D; Spagnolo C; Bongiorno F; Zanardi R; Serretti A; Smeraldi E; Franchini L
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):442-8. PubMed ID: 16431008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS; Benazzi F; Perugi G; Rihmer Z
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.
    Zimmerman M; Posternak MA; Chelminski I
    J Psychiatr Res; 2004; 38(6):577-82. PubMed ID: 15458853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of gender and menopausal status on antidepressant treatment response in depressed inpatients.
    Vermeiden M; van den Broek WW; Mulder PG; Birkenhäger TK
    J Psychopharmacol; 2010 Apr; 24(4):497-502. PubMed ID: 19423613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant response in the elderly.
    Mandelli L; Serretti A; Zanardi R; Rossini D; De Ronchi D; Tarricone I; Colombo C
    Psychiatry Res; 2007 Jul; 152(1):37-44. PubMed ID: 17383015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy.
    van Calker D; Zobel I; Dykierek P; Deimel CM; Kech S; Lieb K; Berger M; Schramm E
    J Affect Disord; 2009 Apr; 114(1-3):243-53. PubMed ID: 18849079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.